期刊文献+

辛伐他汀对中老年高血压患者颈动脉粥样硬化的影响 被引量:5

原文传递
导出
摘要 目的探讨辛伐他汀对中老年高血压患者颈动脉粥样硬化的影响。方法中老年高血压合并颈动脉粥样硬化患者95例,随机分为血脂异常高血压合并颈动脉硬化35例(A组),血脂正常高血压合并颈动脉硬化30例(B组),余30例为对照组(C组)。在常规降压、降糖、抗血小板聚集治疗基础上,A组、B组每晚加用辛伐他汀20mg。分别于治疗前及治疗后6个月测定总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C);彩色多普勒超声检测记录颈动脉内膜-中膜厚度(IMT),并计算颈动脉斑块积分,斑块检出率。结果 C组治疗前后TC、TG、LDL-C、HDL-C水平差异无统计学意义(P>0.05),治疗后IMT、斑块积分上升(P<0.05),斑块检出率增加。A组、B组治疗后除HDL-C上升外,其余血脂指标、IMT及颈动脉斑块积分均较治疗前下降(P<0.05、P<0.01),斑块检出率下降。结论辛伐他汀能延缓和逆转血脂异常或血脂正常中老年高血压患者颈动脉粥样硬化进展,具有稳定斑块作用。
作者 杨利英
出处 《江苏医药》 CAS CSCD 北大核心 2010年第19期2314-2315,共2页 Jiangsu Medical Journal
  • 相关文献

参考文献6

  • 1赵水平.冠心病整体防治中他汀类药物的重要地位[J].中华心血管病杂志,2004,32(4):379-381. 被引量:159
  • 2Rongling LI,Bruce B,Patricia A,et al. B-mode-detected carotid artery plaque in a general population[J], Stroke, 1994, 25 (3) :2377-2383.
  • 3Prisant LM,Zemel PC,Nichols FT,et al. Carotid plaque associations among hypertensive patients[J]. Arch Intern Med, 1993,153(2) : 501-506.
  • 4Crouse JR,HarpoldGH,Kah FR,et al. Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound[J]. Stroke,1986,17(4):270-274.
  • 5许竹梅,赵水平,聂赛,周宏年,李全忠,刘玲.阿托伐他汀增加单核细胞过氧化物酶增殖体激活受体γ表达改善炎症反应[J].中华心血管病杂志,2004,32(4):329-332. 被引量:41
  • 6Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm ( ASCOT-LLA ): a multicentre randomised controlled trial[J]. Lancet, 2003,361(2) : 1149-1158.

二级参考文献11

  • 1Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension, 2002, 40:687-693.
  • 2Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vivo and in vitro by peroxisome proliferators-activator-γ activators. Circulation, 2000,101:235-238.
  • 3Libby P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation, 2001, 104: 365-372.
  • 4Jovinge S, Ares MP, Kallin J, et al. Human monocytes/macrophages release TNF-alpha in responsible to OxLDL. Atherioscler Thromb Vasc Biol, 1996, 16: 1573-1579.
  • 5The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994,344:1383-1389.
  • 6Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atheroslerosis in apolipoprotein E-Knockout mice. Circulation, 2002, 106: 2700-2706.
  • 7Brown DL, Hibbs MS, Kearney M,et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation, 1995, 91:2125-2131.
  • 8Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res, 2002, 91:852-859.
  • 9Baker AH, Edwards DR, Murphy G,et al. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci, 2002, 115:3719-3727.
  • 10Zelvyte I, Dominatiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in responsible to lipoproteins in human monocytes in vitro. Parmacol Res, 2002, 45: 147-154.

共引文献196

同被引文献28

引证文献5

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部